ArticleCancer management and research2026
Impact of Evolving Antiemetic Prophylaxis on Chemotherapy-Induced Nausea and Vomiting (CINV): A Five-Year Comparative Study in Sichuan, China (2018-2023).
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A baseline study conducted in 2018 revealed suboptimal guideline adherence and high chemotherapy-induced nausea and vomiting (CINV) burden in Sichuan, China. Since then, concerted efforts have been made to enhance CINV management through guideline promotion and physician education. This study aimed to evaluate temporal changes in CINV incidence and antiemetic prophylaxis patterns by comparing 2023 real-world data with the 2018 baseline. Methods: In this prospective, multicenter study, we enrolled 1985 cancer patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC) across Sichuan in 2023. We employed methodologies consistent with the baseline study to ensure direct comparability. Primary endpoints were the overall, acute, and delayed CINV incidence. Secondary endpoints included complete control (CC) rates and antiemetic regimen adherence. Results: Compared with the 2018 baseline, significant improvements were observed in 2023. The overall CINV incidence decreased from 82.97% to 57.3% (P < 0.001). Acute CINV decreased from 55.3% to 43.9%, and delayed CINV showed the most substantial decline from 62.3% to 30.4% (P < 0.001 for both). For patients receiving HEC, CC rates in the overall, acute, and delayed phases increased from 30.1% to 58.4%, from 52.8% to 64.1%, and from 60.6% to 75.6%, respectively. For MEC patients, CC rates in the overall, acute, and delayed phases increased from 32.1% to 68.5%, from 47.5% to 83.4%, and from 55.4% to 91.9%, respectively ( Conclusion: Over the five-year period, CINV management in Sichuan has demonstrated significant, measurable progress, evidenced by a notable decline in incidence and substantially improved complete control rates, especially in high-risk HEC patients. This positive trend is strongly associated with the increased implementation of evidence-based antiemetic guidelines. However, the persistent CINV burden underscores the need for continued quality improvement efforts to fully translate guideline recommendations into universal best practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.